%PDF-1.5
%
1 0 obj
<35\). Prostate biopsy was avoided in 50 of 64 patients \(78%\). Of the 11 patients undergoing biopsy for abnormal PCA3, 7 had prostate cancer \(64%\). At >2-year median follow-up, 39 of the remaining 50 patients \(78%\) avoided subsequent biopsy. Only 5 prostate cancers were diagnosed during follow-up. Conclusions: When used in routine clinical practice, PCA3 appears to reduce the number of biopsies being performed in response to elevated PSA. Given the increasing interest in strategies to reduce unnecessary prostate cancer diagnosis and treatment, this FDA-approved and widely-available molecular test appears to achieve these goals. Further testing will clarify the role of PCA3 in initial and subsequent prostate cancer screening paradigms. )/ModDate(D:20131224182709+08'00')/SourceModified(D:20130903092755)/Author(Bradley M. Boelkins, Christopher M. Whelan, Richard J. Kahnoski, Jonathan Todd Bolthouse, Brian R. Lane)/CreationDate(D:20130903172800+08'00')>>
endobj
2 0 obj
<>stream
endstream
endobj
3 0 obj
<>/ProcSet[/PDF/Text]/Font<>/Properties<>>>/MediaBox[0 0 595 808]/StructParents 1/Rotate 0>>
endobj
5 0 obj
<>stream
HWmo_A( bY^,/ɢP$VW|\;/,'YuHg禯6yыyNanS<8
"2Zd" T,(a`ԿR1_6VMWm#|\߬BAŶ;סb9A0,X_Ro).JXx>y.q߯Oo?S?Pd(O%,2d];hu
n#N$UD៉s/HTH2_e-h
%n\/r3!hϑ?G&ɑp^qb-Οث~ꪁU£5:_JM;Q nقiK47|ɰ%jNCEb&A.Aټ@|g y|nW8x$"J`!a`2{2eeh>1zfpiS(dD><9KF;|{;{CSQE5}OM82 K"_ZSdVB~8<,ރy]ONf+*_$nOW>ڂK[td/P>"Ͼ3(
̞|[Pik